Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
704.00    4.00 (0.57%)
Bid:
694.00
Ask:
704.00
Spread: 10.00 (1.441%)
Market Cap: £348.91m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

AGM Statement

16 Jun 2021 07:00

RNS Number : 0171C
Elixirr International PLC
16 June 2021
Β 

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or the "Group")

AGM Statement

Elixirr International plc, an established, global award-winning challenger consultancy, today issues a trading update ahead of its Annual General Meeting to be held later today.

Trading in the five months ended 31 May 2021 has been strong with revenue increasing by more than 75% (including the impact of the acquisition of Coast Digital Limited and The Retearn Group Limited) compared with the same period in 2020. Consequently the Board now expects revenue and Adjusted EBITDA for the year ending 31 December 2021 to be towards the upper end of the range previously indicated to the market, i.e. revenue in the upper range of Β£44-47 million with an Adjusted EBITDA margin of approximately 29%.

The Board looks forward to providing a more detailed update, including on its expectations for the full year, to shareholders in September 2021 with its half year results.

Β 

For further information, please contact:

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

Β 

Public and Investor Relations contacts:

Caroline Pitt

Β 

Β 

Β 

Β 

investor-relations@elixirr.com

Β 

finnCap Ltd (Nominated Adviser & Sole Broker)

ChristopherΒ Raggett,Β SimonΒ Hicks,Β KateΒ BannatyneΒ (CorporateΒ Finance)

Alice Lane, Sunila De Silva (ECM)

Β 

Β 

+44 (0)20 7220 0500

Β 

Β 

Β Β 

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFAMMTMTIBTAB
Date   Source Headline
2nd Jun 20269:49 amRNSNotice of AGM and Dividend Timetable
20th May 20267:00 amRNSIssue of Equity - TRC Contingent Consideration
14th May 20268:38 amRNSHolding(s) in Company
29th Apr 20263:59 pmRNSHolding(s) in Company
29th Apr 202611:18 amRNSPublication of 2025 Annual Report
28th Apr 20265:59 pmRNSResult of Secondary Placing
28th Apr 20264:35 pmRNSProposed Secondary Placing
20th Apr 20267:00 amRNSResults for the year ended 31 December 2025
10th Apr 20267:00 amRNSHolding(s) in Company
27th Mar 20267:00 amRNSNotice of FY 25 Investor Presentation
23rd Mar 20267:00 amRNSGrant of Share Options
19th Mar 202610:09 amRNSDirector/PDMR Shareholding
27th Feb 202610:26 amRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSDirector/PDMR Shareholding
2nd Feb 20267:00 amRNSAcquisition of Kvadrant Consulting A/S
30th Jan 20267:00 amRNSAppointment of Non-Executive Director
22nd Jan 20267:00 amRNSTrading Update and Interim Dividend
9th Jan 20264:37 pmRNSPDMR Shareholding
25th Sep 20258:08 amRNSDirector/PDMR Shareholding
22nd Sep 20257:01 amRNSInterim Results
22nd Sep 20257:00 amRNSAcquisition of TRC Advisory, LLC
18th Sep 20253:28 pmRNSIncrease in Debt Facilities to Support M&A
17th Sep 20257:00 amRNSNotice of H1 25 Investor Presentation
15th Sep 20257:00 amRNSMove from SETSqx to SETS
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSChange of Adviser
1st Jul 20258:00 amRNSReadmission - Elixirr International Plc
1st Jul 20257:00 amRNSAdmission to Main Market
26th Jun 20256:00 pmRNSElixirr International
24th Jun 20253:44 pmRNSPublication of Prospectus
24th Jun 202512:39 pmRNSResult of AGM
10th Jun 20257:00 amRNSGrant of Share Options
30th May 20257:00 amRNSMain Market Update & Capital Markets Day
29th May 20253:58 pmRNSPDMR Dealings and EBT Transfers
29th May 20257:00 amRNSPosting of Annual Report and Accounts
21st May 20257:00 amRNSCapital Markets Day
8th May 202512:21 pmRNSHoldings in Company – Employee Benefit Trust
28th Apr 20257:00 amRNSFinal Results
11th Mar 20257:00 amRNSNotice of FY24 Investor Presentation
18th Feb 20257:00 amRNSTrading Update
22nd Jan 20257:00 amRNSGrant of Restricted Share Awards
17th Jan 20251:40 pmRNSPurchase of Shares by Employee Benefit Trust
16th Jan 20253:05 pmRNSDirector/PDMR Shareholding
13th Jan 20258:06 amRNSBoard Appointment
6th Jan 20257:00 amRNSAppointment of Joint Broker
20th Dec 20244:20 pmRNSDirector/PDMR Shareholding
20th Dec 20247:00 amRNSInterim Dividend
10th Dec 20247:00 amRNSBoard Changes
25th Nov 20247:00 amRNSChange of Adviser
31st Oct 20247:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.